A rare case report of reversible glucose counterregulation in an insulinoma patient with type 2 diabetes
Endocrine · 09.02.2024 · 84 (3) · 885-889
DOI: 10.1007/s12020-024-03703-9 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrine, online erschienen am 09.02.2024. Verfasst von Jian-Hui Teng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 41005, Hunan Province, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Committee of Hunan Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Insulinoma is a neuroendocrine tumor derived from pancreatic β -cells whose clinical manifestation is recurrent hypoglycemia. Insulinoma in a patient with preexisting diabetes is extraordinarily rare, and the unmasking of type 2 diabetes (T 2 DM) after insulinoma surgery is even rarer. Case report This article reports a 49-year-old male patient with insulinoma that masked the diagnosis of T 2 DM. The patient was admitted to the hospital with symptoms of hypoglycemia, such as repeated sweating, palpitations, and asthenia for over 4 years. The patient was diagnosed with insulinoma after completing relevant examinations. The emergence of hyperglycemia after the removal of insulinoma is attributable to the coexistence of T 2 DM. Surprisingly, a reversible decrease in cortisol levels was observed during the diagnostic process. We searched the previously published reports of this type of case from PubMed to determine why type 2 diabetes was covered by insulinoma and why glucocorticoids decreased.
Conclusions
The diagnosis of T 2 DM in the patient after surgery may be related to increased food intake and insulin resistance induced by hyperinsulinemia caused by long-term hypoglycemia. The reversible decrease in cortisol levels, not adrenocortical insufficiency during the diagnostic process, may be caused by a transient abnormality in glucose counterregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 41005, Hunan Province, China.
- Department of Endocrinology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 41005, Hunan Province, China.
- Department of Endocrinology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 41005, Hunan Province, China. chenjingnfmk@163.com.
ORCID-Profile: Jing Chen
Förderung
- Health Committee of Hunan Province
Zitieren
APA
Teng, J. H., Hu, J. P., Wang, X., Zhang, C., & Chen, J. (2024). A rare case report of reversible glucose counterregulation in an insulinoma patient with type 2 diabetes. Endocrine, 84(3), 885-889. https://doi.org/10.1007/s12020-024-03703-9
Vancouver
Teng JH, Hu JP, Wang X, Zhang C, Chen J. A rare case report of reversible glucose counterregulation in an insulinoma patient with type 2 diabetes. Endocrine. 2024;84(3):885-889. doi:10.1007/s12020-024-03703-9
BibTeX
@article{Teng2024,
author = {Teng, Jian-Hui and Hu, Jun-Pei and Wang, Xia and Zhang, Chi and Chen, Jing},
title = {A rare case report of reversible glucose counterregulation in an insulinoma patient with type 2 diabetes},
journal = {Endocrine},
year = {2024},
volume = {84},
number = {3},
pages = {885--889},
doi = {10.1007/s12020-024-03703-9}
}
EUVIMED